Skip to main content
S&P 5007,771.71-0.39%DOW50,950.43-0.45%NASDAQ27,390.17-0.54%BTC$81,568.00-1.70%ETH$2,474.58-3.35%GOLD$4,139.00-0.04%OIL$93.01+5.36%
Smart Investors Daily
SID Premium
SL

NASDAQ · SLGL

Sol-Gel Technologies Ltd.

Healthcare · Biotechnology

$71.95

Down-$3.38 (-4.69%)

Updated Oct 8, 2026, 2:07 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
116.7M
P/E ratio
-34.22
Dividend yield
0.00%
52-week range
$58.30 – $96.00
Volume
31.33K
Avg. volume
17.87K

Price performance · SLGL

SLGL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

SLGL closed at $71.95 after 21 trading sessions, up 4.00% for the selected period.

Last close
$71.95
Period change
+4.00%
Period low
$59.28
Period high
$78.95
Daily close
View OHLC price history
SLGL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$74.97$75.065$71.28$71.94531.33K
Oct 6, 2026$78.95$79.50$73.945$75.6443.98K
Oct 5, 2026$71.20$79.01$71.20$78.9529.25K
Oct 2, 2026$72.88$74.35$70.84$72.0044.37K
Oct 1, 2026$74.42$74.42$70.75$73.0032.76K
Sep 30, 2026$73.33$77.67$72.87$74.2839.18K
Sep 29, 2026$69.96$72.785$69.20$72.2530.68K
Sep 28, 2026$66.72$72.00$66.72$69.4557.95K
Sep 25, 2026$61.25$67.29$61.05$66.8526.07K
Sep 24, 2026$59.57$62.63$58.415$60.7466.87K
Sep 23, 2026$61.00$61.77$58.73$59.7170.68K
Sep 22, 2026$58.79$63.70$58.79$60.9579.72K
Sep 21, 2026$59.83$60.00$58.30$59.2829.77K
Sep 18, 2026$64.17$64.61$60.00$60.0045.86K
Sep 17, 2026$62.65$65.44$62.64$64.5445.14K
Sep 16, 2026$64.46$64.46$60.98$63.4454.46K
Sep 15, 2026$64.25$66.50$64.00$64.4059.13K
Sep 14, 2026$65.69$66.39$64.02$65.1827.93K
Sep 11, 2026$67.42$67.62$65.605$65.9425K
Sep 10, 2026$69.40$69.57$66.10$66.7984.21K
Sep 9, 2026$70.99$70.99$68.42$69.1847.71K

Latest SLGL news

The latest Smart Investors Daily articles mentioning SLGL.

Stock researchCompany · Overview

SLGL research

Overview

Company profile and research snapshot.

Company profile

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$50.00
Implied upside
—
Analysts
7
SLGL recent ratings
DateFirmRatingTarget
Jul 20, 2026HC Wainwright & Co.Buy—
Jun 24, 2026MizuhoOutperform—
Jan 20, 2026HC Wainwright & Co.Buy—
Dec 22, 2025HC Wainwright & Co.Buy—
Oct 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026

NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York. The event will feature Julie Breneiser, PA-C (Gorlin Syndrome Alliance), Ervin Epstein Jr., MD (Alta Bates Summit Medical Center), Kavita Sarin, MD, PhD (Stanford Cancer Institute),

Yahoo · Sep 17, 2026

SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Yahoo · Sep 17, 2026

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndromeTop-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company's pivo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By